Increased prevalence of obstructive sleep apnea in women diagnosed with endometrial or breast cancer

Ayey Madut1,2, Veronika Fuchsova1,2, Hong Man1,2, Shabeel Askar1,2, Ritu Trivedi1,2, Elisabeth Elder1,2,3, Terence Amis1,2,6,7, Kristina Kairaitis1,2,6,7

1 Ludwig Engel Centre for Respiratory Research, The Westmead Institute for Medical Research, Sydney, Australia, 2 Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia, 3 Breast Cancer Institute, Westmead Hospital, Sydney, Australia, 4 Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, Australia, 5 Department of Gynecological Oncology, Westmead Hospital, Sydney, Australia, 6 Sydney West Translational Cancer Research Centre, Sydney, Australia, 7 Department of Respiratory and Sleep Medicine, Westmead Hospital, Sydney, Australia

Abstract

Background
Epidemiological studies demonstrate associations between obstructive sleep apnea (OSA) and cancer incidence and mortality. The aim of this study was to measure OSA in women with breast (BC) or endometrial cancer (EC) and associations with clinico-pathological tumor variables.

Methods and findings
In a cross sectional study, women with BC (12 months) or EC (3 months) post-diagnosis were recruited from cancer clinics. We collected demographic, anthropometric data, cancer stage, grade, histopathology and history of cancer treatment and all subjects had in-laboratory polysomnography. Sleepiness was assessed with the Epworth Sleepiness Scale (ESS). We compared anthropometric and polysomnographic data between cancer groups (unpaired t-tests), and assessed relationships between cancer characteristics and OSA variables (Fishers exact test). There were no significant differences between average age (BC: 59.6±8.7 years (n = 50); EC: 60.3±7.7 years (n = 37)), or ESS score (BC: 6.4±4.4; EC: 6.8±4.7; mean±SD; all p>0.2), however, BMI was higher in EC (BC: 29.7±7.9kgm⁻²; EC: 34.2±8.0kgm⁻²; p<0.05). BC had longer sleep latency (BC: 31.8±32 minutes; EC: 19.3±17.9 minutes), less Stage 3 sleep (BC: 20.0±5.2%; EC: 23.6±8.2%) and more REM sleep (BC: 21.1±6.9%; EC: 16.6±5.7%), all p<0.05. EC had lower average awake and asleep oxygen saturation levels (BC: 95.6±1.3%; EC: 94.6±1.9% [awake]; BC: 94.8±2.1%; EC: 93.3±2.4% [asleep]; both p<0.05). Apnea-Hypopnea Index (AHI) (BC: 21.2(7.3–36.9) events/hr; EC: 15.7 (10–33.5) events/hour (median (interquartile range)) was not different p = 0.7).
however, 58% and 57% of women with BC and EC respectively, had an AH1>15 events/hour. In this small sample size group, no significant associations (all p>0.1) were detected between OSA metrics and clinico-pathological tumor variables.

**Conclusion**

In postmenopausal women with breast or endometrial cancer there is high prevalence of OSA, with no association with specific tumor characteristics detected. Recognition of the high prevalence of OSA in women with cancer is important to recognise as it may impact on surgical risk and quality of life.

**Introduction**

A number of epidemiological studies have reported increased mortality rates in cancer patients with co-morbid obstructive sleep apnoea (OSA) [1, 2]. Across a number of cancer types, individuals with severe OSA have an adjusted hazard ratio of 4.8 for dying as a consequence of cancer progression [1]. When intermittent hypoxia, a physiological consequence of recurrent upper airway obstruction during sleep, is considered, this relationship becomes even stronger with an estimated hazard ratio of 8.6 for patients with severe levels of nocturnal oxygen desaturation [1]. In an Australian population study, moderate to severe OSA was associated with an adjusted cancer mortality odds ratio (OR) of 3.4, and a cancer incidence OR of 2.5 [2].

Most reports to date have focused on retrospective data across a variety of cancer types. Prospective studies examining associations between OSA and specific cancers are sparse. However, studies have reported associations between sleep disordered breathing and cutaneous melanoma [3, 4], while another has reported a high prevalence of OSA in lung cancer patients [5].

For women with cancer in particular, little attention has been paid to potential OSA-cancer associations, and even the prevalence of OSA in these cohorts is mostly unknown. For breast cancer patients, one prospective study of 83 breast cancer patients found a prevalence rate for moderate-severe (apnea hypopnea index >15 events/hour) OSA of 13%, although they could find no link between markers of cancer aggressiveness and sleep disordered breathing [6]. This lack of information is particularly problematic given obesity is a known major risk factor for both OSA and a number of cancers in women, in particular, endometrial cancer and post-menopausal breast cancer [7]. In addition, in these female cohorts, there are also potential sleep-disorder-promoting interactive factors at play, some of which are linked to cancer risk factors themselves (eg age, menopause, obesity). For some female cancers, risk factors shared with OSA are particularly strong (eg obesity and endometrial cancer [7–9]).

In the present study, the prevalence of OSA in women with breast and endometrial cancer was measured using prospective, in-laboratory, polysomnography data. A secondary aim was to test for potential linkages between the severity of sleep disordered breathing and tumour histopathology markers, particularly those associated with tumour aggressiveness.

**Materials and methods**

All subjects were prospectively recruited from cancer clinics at Westmead Hospital between May 2016-March 2019. Subjects were approached in person by the researcher in the clinic and asked if they would participate in a study regarding sleep and cancer. All subjects gave written
informed consent and the protocol was approved by the Western Sydney Local Health District Human Research Ethics Committee.

Subjects
All women recruited had a previous diagnosis of endometrial or breast cancer. Prior to recruitment, all had completed a course of cancer therapy that included surgery, and/or radiotherapy and/or chemotherapy. Women with endometrial cancer (n = 37) were recruited 8–12 weeks following surgical treatment (hysterectomy), while women diagnosed with breast cancer (n = 51) were recruited 12 months after completion of primary treatment. Breast cancer patients on anti-oestrogen therapy, including tamoxifen or aromatase inhibitors, were included in the study. Data collected included other comorbidities, as well as primary (e.g. surgery, radiotherapy, chemotherapy) and ongoing treatment regimens. Patients were not included if they had previously been diagnosed with OSA.

Anthropometric data
Age was recorded and anthropometric data including height, weight and neck circumference were measured at the time of recruitment.

Cancer histopathology
Information regarding histopathology and cancer treatment regimes was collected from the patient’s medical record. For women with breast cancer, this included: Nottingham tumor grade [10], tumour size and stage, cancer subtype, estrogen or progesterone receptor staining, staining for Ki67 (a marker of cell proliferation), human epidermal growth factor 2 (HER2), and mitotic index. For women with endometrial cancer, data were collected regarding histological subtype (endometrioid, serous, mixed or clear cell), grade, FIGO stage [11], and staining for estrogen receptor, progesterone receptor and the tumor suppressor TP53.

Assessment of sleepiness and OSA risk
Subjects completed an Epworth Sleepiness Scale (ESS) [12] questionnaire to document subjective sleepiness. A STOP BANG questionnaire [13] was completed to assess risk of OSA. A STOP BANG score greater than 3 was considered to indicate OSA risk [14].

Polysomnography
All subjects underwent full in-laboratory overnight polysomnography with monitoring of EEG, EOG, chin, diaphragm and pre-tibial EMG, nasal pressure, oro-nasal thermistor signals, sound (snoring), thoracic and abdominal plethysmography and oximetry. Studies were scored according to American Academy of Sleep Medicine criteria [15]. Values for total sleep time, sleep efficiency, sleep onset latency, wake after sleep onset (minutes, WASO), sleep stage (% sleep time), apnea hypopnea index (AHI, events per hour sleep), respiratory disturbance index (RDI, events per hour of sleep), central apnea index (events/hour), average oxygen saturation level (SpO2 awake) obtained in the upright awake seated position for 3 minutes before sleep, average oxygen saturation during sleep (SpO2 sleep), oxygen desaturation index (ODI3%), and total sleep time with an oxygen saturation less than 90% (mins, TST<90%) were obtained for each subject.
Statistical analysis

Sample size and power calculation: The study sample size was not based on a power calculation and therefore this study should be considered exploratory only.

This study was designed a cross-sectional observational study with the main outcomes based on comparisons between two exclusively female cancer-type patient groups. Group mean and standard deviation, or median and interquartile ranges for non-normally distributed data were calculated as appropriate. Anthropometric and sleep data for each female cancer patient cohort were compared using unpaired two-tailed t-tests. Data that were not normally distributed (AHI, ODI, TST <90%, nadir SpO2(%) ) were compared using an independent samples median test with Yates continuity correction. \( p < 0.05 \) was considered significant.

Relationship between indices of sleep disordered breathing and cancer histopathological characteristics. Exploratory analyses were performed to assess for relationships between markers of sleep disordered breathing severity and histopathological markers. Two categorical sleep-disordered-breathing-severity metric based sub-groups for each cancer group were constructed using (separately) values \( \geq \) or \(< \) the median values for AHI, RDI, ODI (3%) and TST <90% contained in the data set for that cancer cohort (ie a total of 2x4 sub-groups). For endometrial cancer patients, a median AHI of 15.7 events per hour, ODI of 10 events per hour, RDI of 18.9 events per hour and TST < 90% of 2.4% were used. For breast cancer patients, categories were assigned using a median AHI of 21.5 events per hour, ODI of 7.3 events per hour, RDI of 23.8 events per hour and TST < 90% of 0.5%. Relationships between these categorical sleep disordered-breathing severity sub-groups and histopathological markers were compared using Fisher’s exact test. For the women with breast cancer, relationships between the categorical variables of sleep apnea severity and; Ki67 staining (\( \leq 15\% \), >15% staining), mitotic index, estrogen receptor staining, progesterone receptor staining, HER2 receptor staining, tumour grade were examined. For endometrial cancer the relationships between the categorical variables of sleep apnea severity and tumor grade and FIGO stage were examined. There was insufficient data to analyse the relationships with estrogen and progesterone receptors or TP53, as all cancers stained for estrogen receptor, only one endometrial cancer was negative for the progesterone receptor and only 7 stained for TP53. As there were few stage III and IV endometrial cancers, analysis was confined to Stage I, and Stage II-IV tumours.

Results

A total of 51 women diagnosed with breast cancer and 37 diagnosed with endometrial cancer consented to participate in the study and were included. One breast cancer patient only slept for 90 minutes during the polyomnography study and therefore all their data was excluded from the analysis.

Anthropometric data

Anthropometric and ESS questionnaire data are shown in Table 1. Both groups of women were predominantly middle aged, and there was no significant difference in mean age between the groups (BC, 59.6 \( \pm \) 8.7 yrs; EC, 60.3 \( \pm \) 7.7 yrs). However, endometrial cancer patients were more likely to be obese (BMI: BC: 29.7 \( \pm \) 7.9 kg/m\(^2\); EC: 34.2 \( \pm \) 8.0 kg/m\(^2\); \( p < 0.05 \)). On average, neither group of women had subjective sleepiness, with an average ESS less than 10 [12], and there was no significant difference between the groups (\( p = 0.67 \)). STOP-BANG scores were significantly higher in women with endometrial cancer (\( p < 0.04 \)), while 46% of patients with
breast cancer and 57% of patients with endometrial cancer had a STOP-BANG score greater than or equal to 3 (Table 1).

Cancer histopathology

Breast cancer. The majority of patients had a history of a ductal malignancy (42/50, 84%), and most cases for which data were available were positive for progesterone (40/46, 87%) and/or estrogen receptors (42/45, 93%). Only two women had triple negative breast cancer (ie were negative for HER2, estrogen receptor or progesterone receptor) (Table 2a).

Endometrial cancer. The majority of women in this cancer group had a histopathological diagnosis of Grade 1 (FIGO Stage 1 or II) endometrioid cancer. The majority of tumours were positive for progesterone and/or estrogen receptors, and seven of the tumours stained for TP53 (Table 2b).

Cancer treatment. Treatment for BC. 1) 13 (26%) of patients had a mastectomy, the remainder had a lumpectomy; 2) 39 (78%) of patients had adjuvant radiotherapy, 3) 27 (54%) had chemotherapy, and 4) 34 (68%) of patients were on a current hormonal treatment (either tamoxifen or an aromatase inhibitor).

Treatment for EC. 1) all patients underwent a hysterectomy, 2) 15 (40.5%) of patients received adjuvant radiotherapy, and 3) 5 (13.5%) patients received adjuvant chemotherapy.

Sleep architecture. Total sleep time and sleep efficiency were not significantly different between the two groups. However, women with breast cancer had a longer sleep latency duration, less slow wave sleep and a greater proportion of rapid eye movement sleep than the endometrial cancer group (Table 3).

Hypoxia metrics and sleep disordered breathing

The endometrial cancer group had significantly lower average oxygen saturation levels during wakefulness. There were no significant differences between the two cancer groups for the severity of sleep disordered breathing (as measured by AHI and RDI). Measures of nocturnal oxygen saturation (ODI, TST<90%) also did not differ between the groups. However, 58% of the breast cancer patients, and 57% of endometrial cancer patients had an AHI >15 events per hour, while 32% of the breast cancer cohort and 32.4% of the endometrial cancer cohort had an AHI >30 events per hour. Women with endometrial cancer had a higher central apnea index (p<0.03) (see Table 3, Fig 1).
Table 2. (a) Histopathological data for breast cancer patients. (b) Histopathological data for endometrial cancer patients.

(a) Histopathological type

| Histopathological type | Number (%) |
|------------------------|------------|
|                       | n = 50*   |
| Ductal                | 42 (84%)  |
| Lobular               | 7 (14%)   |
| Other                 | 1 (2%)    |

Immunohistochemistry

| Estrogen receptor (n = 45) | Number (%) |
|---------------------------|------------|
| ER-positive               | 42 (93%)   |
| ER-negative               | 3 (7%)     |
| Not known (n = 5)*        |            |

| Progestrone receptor (n = 46) | Number (%) |
|-------------------------------|------------|
| PR-positive                   | 40 (87%)   |
| PR-negative                   | 6 (13%)    |
| Not known (n = 4)*            |            |

| HER2 receptor (n = 42) | Number (%) |
|------------------------|------------|
| HER2-positive          | 4 (19%)    |
| HER2 negative          | 38 (90%)   |
| Not known (n = 8)*     |            |

| Triple negative        | 2 (5%)     |
| Ki67 (n = 43)          |            |
| Ki67 \( \leq 15\% \)   | 18 (42%)   |
| Ki67 >15\%             | 25 (50%)   |
| Not known (n = 7)*     |            |

| Mitotic Index (n = 41) | Number (%) |
|------------------------|------------|
| \(<6\% \)              | 21 (51%)   |
| 6–10%                  | 4 (10%)    |
| >10%                   | 16 (39%)   |
| Not known (n = 9)*     |            |

Nottingham histological grade (n = 48)

| Grade | Number (%) |
|-------|------------|
| Grade 1| 13 (27%) |
| Grade 2| 17 (35%) |
| Grade 3| 18 (38%) |
| Not known (n = 2)* |   |

(b) Histopathological Subtype

| Histopathological Subtype | Number (%) |
|---------------------------|------------|
|                        | n = 37*    |
| Endometrioid             | 32 (86.5%) |
| Serous                   | 0          |
| Clear Cell               | 1 (2.7%)   |
| Mixed                    | 2 (5.4%)   |
| Other                    | 2 (5.4%)   |

| Grade (n = 36) | Number (%) |
|----------------|------------|
| Grade 1        | 23 (64%)   |
| Grade 2        | 9 (25%)    |
| Grade 3        | 4 (11%)    |
| Not known (n = 1)* |         |

(Continued)
Relationships with tumour histopathological characteristics

For both breast and endometrial cancer patients, there were no significant differences in the prevalence of any histopathological marker between the two sleep disordered breathing severity sub-groups (based on any polysomnography metric) (all p > 0.09, Fisher’s Exact test, see Table 4, Fig 2).

Discussion

This is the first study to compare polysomnography findings for women across two specific post-treatment cancer patient groups, breast and endometrial cancer. In doing so, we also report the first study to examine the prevalence of OSA in women diagnosed with endometrial cancer; a female cancer cohort with the OSA-shared risk factor of obesity.

The major finding of this study is that more than half of the women in each of these cancer patient groups were found to have at least moderate OSA (AHI > 15 events/hr), and nearly one third had severe OSA (AHI > 30 events/hr). There were no differences between the two cancer patient groups in terms of the overall severity of OSA, although women with endometrial...
cancer had slightly lower average oxygen saturation levels, both awake and asleep. Excessive sleepiness was not a feature of either of these cohorts. There were no associations between measurements of OSA severity and any tumour histopathological feature or malignancy grade within either cohort.

Prevalence of sleep disordered breathing in women with a history of cancer

In this study of female cancer, OSA prevalence was greater than that reported for community-based population studies. Based on previous data [16], and adjusted for increasing obesity prevalence [17] it has been estimated that 9% (confidence interval 7–11%) of women between 50–70 years have moderate-severe OSA (AHI > 15 events per hour). The more recent Hypnolau study suggests a population prevalence of 23.4% for moderate-severe OSA (AHI > 15 event/hr) in women with an average age of 58 years [18]. The prevalence of OSA in both female cancer cohorts is higher than population prevalence; however, similar to that reported in obese postmenopausal women of 67% with an RDI greater than 10 events per hour [19]. Based on the STOP-BANG score, at least half of the patients were at risk for OSA, however, age and obesity would have resulted in the majority of patients scoring at least 1 on this questionnaire. This increased prevalence compared to the population is most likely a consequence of shared risk factors for breast cancer, endometrial cancer and OSA of obesity and

| Table 3. Group average data for sleep architecture measures, hypoxia metrics and sleep disordered breathing (SDB) severity metrics for the two cancer cohorts. |
|--------------------------------------------------|------------------|------------------|------------------|
| Sleep Architecture                              | Breast Cancer (n = 50) | Endometrial Cancer (n = 37) | P value |
| Total Sleep Time (mins)                         | 359.8±67.6        | 366.3±67.3        | 0.67            |
| Sleep Latency (mins)                            | 31.8±32           | 19.3±17.9*        | 0.03            |
| Stage 1 (%)                                     | 7.8± 6.3          | 10.1±9.7          | 0.18            |
| Stage 2 (%)                                     | 49.9± 9.7         | 48.5± 11.6        | 0.55            |
| Stage 3 (%)                                     | 20.0 ± 5.2        | 23.6 ±8.2*        | 0.02            |
| REM (%)                                         | 21.1±6.9          | 16.6±5.7*         | 0.02            |
| WASO (minutes)                                  | 83.6 ±58.8        | 95.5 ±51.4        | 0.33            |
| Arousal index (events/ hr)                      | 26.8±14.9         | 28.3±17.5         | 0.66            |
| Sleep Efficiency (%)                            | 76.0±13.4         | 76.6±12.1         | 0.96            |
| SDB and Hypoxia Metrics                         |                   |                   |                 |
| Average SpO2 awake                              | 95.6±1.3          | 94.6±1.9*         | 0.003           |
| Average SpO2 during sleep                       | 94.8±2.1          | 93.3±2.5*         | 0.006           |
| AHI (events/hr)                                 | 21.2 (7.3–36.9)   | 15.7 (10–33.5)    | 0.733           |
| AHI Categories n (%)                            |                   |                   | 0.00            |
| AHI <5 events/hr                                | 6 (12)            | 6 (16)            |                 |
| 5 to <15 events/hr                              | 15 (30)           | 10 (27)           |                 |
| 15 to <30 events/hr                             | 13 (26)           | 9 (24)            |                 |
| >30 events/hr                                   | 16 (32)           | 12 (32)           |                 |
| RDI (events/hr)                                 | 23.8 (7.9–38.9)   | 18.9 (10–34)      | 0.44            |
| Central apnea index(events/hr)                  | 0.0 (0.0–0.2)     | 0.2 (0.0–0.5)     | 0.03            |
| ODI (3%)                                        | 7.3 (1.9–18)      | 10.0 (2.4–20.9)   | 0.6              |
| TST <90%                                        | 0.45 (0–3.8)      | 2.4 (0.15–9.7)    | 0.25            |
| Nadir SpO2(%)                                   | 86 (78–91)        | 84 (75.5–89)      | 0.4              |

Data are mean±standard deviation, or median, interquartile ranges (AHI, RDI, ODI, TST<90%, Nadir SpO2(%)) or n (%) for AHI categories,

* = p<0.05.
Endometrial cancer is one of the cancers most strongly associated with obesity, however obesity is also a risk factor for post menopausal breast cancer [7].

The prevalence of OSA in breast cancer patients reported in the present study is higher than previously reported. A study of 83 breast cancer patients in Spain, with an average age of 48.8 years, estimated moderate-severe OSA prevalence (AHI > 15 events/hr) at only 13.3% [6]. That study used limited channel home sleep studies and nearly half of the women were premenopausal, both of which may have reduced the measured prevalence. In another study of breast cancer patients after treatment, which specifically excluded women with a history of snoring but used polysomnography, there were no women with moderate to severe OSA [20]. We could find no previous polysomnography study reports in women with endometrial cancer.

The OSA prevalence in the present study was such that nearly one third of both cancer cohorts reached a severity level for sleep disordered breathing that warranted treatment, and based on STOP-BANG screening, almost half the breast cancer patients and two thirds of the endometrial cancer patients were at high risk of having OSA. A lack of recognition and diagnosis of sleep disordered breathing in women is an issue that has been identified by others [21]. The reasons for this underdiagnosis may be a consequence of an absence of either subjective or objective sleepiness, as has been reported by others [22, 23], and which was also present in both our female cancer patient groups. The reasons for this high prevalence in these female cancer patients are not clear. It is most likely related to the presence of shared risk factors (obesity, age, postmenopausal status) for OSA and both endometrial and breast cancer in these cohorts [7, 24–26]. However we are cognisant that there is potential for patient self-selection bias in a volunteer cohort sleep study, and not all patients who met criteria for a sleep study in this study volunteered to have one, likely further enriching the sample for women with OSA.

Fig 1. Individual data for breast cancer and endometrial cancer patients for: (A) apnea hypopnea index (AHI) and (B) respiratory disturbance index (RDI). Bars represent median and interquartile range, dotted lines are at 15 events/hour (moderate OSA) and 30 events per hour (severe OSA), closed circles are breast cancer patients, open circles are endometrial cancer patients.

https://doi.org/10.1371/journal.pone.0249099.g001
Table 4. Distribution of histopathological characteristics across the categorical variables for sleep disordered breathing for (a) breast cancer and (b) endometrial cancer.

(a)  

|                | AHI (events/hour) | ODI (events/hour) | TST<90 (%) | RDI (events/hour) |
|----------------|-------------------|-------------------|------------|-------------------|
|                | <21.5             | ≥21.5             | <7.3       | >7.3              | <0.5           | ≥0.5           | <23.8        | ≥23.8        |
| Estrogen receptor (n = 45) |                   |                   |            |                   |                |                |              |              |
| ER-positive (n) | 21                | 21                | 21         | 21                | 22             | 20             | 21           | 21           |
| ER-negative (n) | 2                 | 1                 | 2          | 1                 | 2              | 1              | 2            | 1            |
| p              | 0.7               | 0.7               | 0.6        | 0.7               |                |                |              |              |
| Progesterone receptor (n = 46) |                   |                   |            |                   |                |                |              |              |
| PR-positive (n) | 22                | 18                | 23         | 17                | 23             | 17             | 22           | 18           |
| PR-negative (n) | 2                 | 4                 | 1          | 5                 | 1              | 5              | 2            | 4            |
| p              | 0.5               | 0.1               | 0.1        | 0.3               |                |                |              |              |
| HER2 receptor (n = 42) |                   |                   |            |                   |                |                |              |              |
| HER2 positive (n) | 3                 | 1                 | 3          | 1                 | 3              | 1              | 3            | 1            |
| HER2 negative (n) | 20                | 18                | 20         | 18                | 20             | 18             | 20           | 18           |
| p              | 0.2               | 0.2               | 0.2        | 0.2               |                |                |              |              |
| Ki67 staining (n = 43) |                   |                   |            |                   |                |                |              |              |
| Ki67 <15%       | 9                 | 9                 | 8          | 10                | 9              | 9              | 8            | 10           |
| Ki67 >15%       | 14                | 11                | 15         | 10                | 14             | 11             | 15           | 10           |
| p              | 0.4               | 0.2               | 0.4        | 0.2               |                |                |              |              |
| Mitotic Index   |                   |                   |            |                   |                |                |              |              |
| <6%            | 11                | 10                | 10         | 11                | 11             | 10             | 11           | 10           |
| 6–10%          | 2                 | 2                 | 2          | 2                 | 2              | 2              | 2            | 2            |
| >10%           | 9                 | 7                 | 10         | 6                 | 8              | 8              | 9            | 7            |
| P              | 0.8               | 0.5               | 1.0        | 0.8               |                |                |              |              |
| Nottingham Grade |                   |                   |            |                   |                |                |              |              |
| Grade 1        | 9                 | 4                 | 8          | 5                 | 9              | 4              | 9            | 4            |
| Grade 2        | 5                 | 12                | 5          | 12                | 6              | 11             | 5            | 12           |
| Grade 3        | 10                | 8                 | 11         | 7                 | 9              | 9              | 10           | 8            |
| p              | 0.2               | 0.1               | 0.3        | 0.2               |                |                |              |              |

(b)  

|                | AHI (events/hour) | ODI (events/hour) | TST<90 (%) | RDI (events/hour) |
|----------------|-------------------|-------------------|------------|-------------------|
|                | <15.7             | ≥15.7             | <10        | >10               | <2.4           | ≥2.4           | <8.9        | ≥8.9        |
| Grade (n = 36) |                   |                   |            |                   |                |                |              |              |
| Grade 1 (n)    | 10                | 13                | 12         | 11                | 11             | 12             | 5           | 18           |
| Grade 2 (n)    | 4                 | 5                 | 3          | 6                 | 5              | 4              | 1           | 8            |
| Grade 3 (n)    | 3                 | 1                 | 2          | 2                 | 2              | 4              | 1           | 3            |
| p              | 0.6               | 0.8               | 1.0        | 0.3               |                |                |              |              |
| FIGO Stage (n = 35) |                   |                   |            |                   |                |                |              |              |
| I              | 12                | 14                | 14         | 12                | 14             | 12             | 6           | 20           |
| II-IV          | 5                 | 4                 | 3          | 6                 | 4              | 5              | 1           | 8            |
| p              | 0.8               | 0.7               | 0.8        | 0.3               |                |                |              |              |

P values are results of Fisher’s exact test (2-sided significance).

https://doi.org/10.1371/journal.pone.0249099.t004
A high OSA prevalence may also be a reflection of an underlying association between OSA and cancer incidence [1, 2, 27] which has been reported to be particularly high in women [28]. Some epidemiology studies have also reported that OSA is a specific risk factor for breast cancer [29, 30], although other studies have failed to demonstrate this relationship [27].

**Generalisability and clinical relevance.** All women in this study were well known to the health system and were receiving specialised care for their cancer, despite this, their OSA status remained undiagnosed. Irrespective of the potential interaction between OSA and cancer incidence and mortality, there are important health, quality of life and clinical management issues associated with undiagnosed OSA. Epidemiological studies suggest that in women associations between OSA and hypertension [31], and cardiovascular disease [32, 33] are stronger than in men. Similarly OSA in women is associated with systemic inflammation at lower levels of sleep disordered breathing than men [34]. Finally, recent data demonstrates that unrecognised severe OSA (AHI>30 events/hr) increases the risk of perioperative cardiovascular events [35]. We did not collect data on cardiovascular risk in this study, however all of the women in this study had undergone surgical procedures as part of their cancer treatment. Identification of OSA in this group of women with cancer is important for both short term management of peri-operative risk, and longer term management of inflammation and cardiovascular disease.

**Relationships between metrics of sleep disordered breathing and cancer aggressiveness**

We were unable to demonstrate any relationships between histopathological features of cancer aggressiveness and any metric of sleep disordered breathing in either group, although we
recognise that the cohorts are relatively small for analysis of multiple clinical variables. In particular, within the breast cancer cases, few cases were negative for estrogen, progesterone and HER-2 receptors. Similarly, small numbers of endometrial cancer cases stained for TP53, or were negative for reproductive hormones.

Risk factors for specific cancers vary, and existing evidence suggests OSA pathophysiology may not interact with all cancers. Our findings are similar to recent findings in 83 women with breast cancer [6]. These women were younger than our cohort, with a lower prevalence of moderate-severe sleep disordered breathing, although grade and histopathological subtype of the cancers present were similar [6]. The limitations on the present study for finding an interaction include that participant numbers, particularly for endometrial cancer patients, were not powered to investigate interactions between OSA and cancer aggressiveness, nor was there sufficient heterogeneity in the cancer histopathology to demonstrate a signal. Within the endometrial cancer patients, the majority of the subject group were low grade endometrioid tumours. However, our findings in the breast cancer patients are in agreement with previous reports [6]. There have been no previous investigations of relationships between endometrial markers of cancer aggressiveness and sleep disordered breathing, and our negative findings are the first to be reported.

A lack of molecular subtyping of tumours may also have limited our ability to demonstrate significant interactions between tumours and sleep disordered breathing. Endometrial cancer can be divided into four molecular subtypes [36], which differ despite similar histopathological appearances. Similarly, there is a great deal of heterogeneity in breast cancer molecular subtypes [37]. Systemic fluctuating oxygen levels, or intermittent hypoxia, has been demonstrated to alter genotypes and phenotypes of epithelial cell lines, with reduction in TP53 expression (a tumour suppressor gene) and increasing the expression of hypoxic inducible factor alpha (HIF1a) [38]. Intermittent hypoxia is a feature of both groups of cancer patients in this study, and molecular subtyping of the tumours may provide more insight into interactions with OSA.

Finally, this was a study of cancer patients after treatment, and sleep studies were performed 12 months (breast cancer) and 3 months (endometrial cancer) after initial diagnosis. Severity of OSA measured at this time point may not be reflective of OSA severity prior to the cancer diagnosis.

Sleep architecture and OSA differences between women with cancer

There were differences between the two groups in terms of sleep architecture, with women with endometrial cancer having less REM sleep, more slow wave sleep and a shorter sleep latency. Apart from obesity, there were no significant demographic differences between the two groups. Obesity is reported to reduce slow wave sleep with no effect on REM sleep in men [39], although others have reported no relationship between BMI and SWS and REM in larger population samples [40]. Thus, reasons for differences in sleep architecture are not clear. Women with breast cancer complain of poor sleep, and up to 60% of women highlight this as an issue after breast cancer treatment [41]. There are few studies in women with endometrial cancer, however, one study found that 61% of women with endometrial cancer had subjective poor sleep quality [42]. Postmenopausal status may have influenced sleep architecture. A recent extensive review of polysomnographic studies in women during the menopausal transition, concluded there are few consistent effects of menopausal stage on sleep architecture [43]. However, slow-wave sleep is more prevalent in a large population samples of post versus premenopausal women and postmenopausal women on hormone replacement with oestrogen and progesterone also have less slow wave sleep [43]. Differences between the two cancer
groups in sleep architecture in the present study may be related to differences in reproductive hormone levels.

There were no significant differences between the two groups of female cancer patients in terms of the severity of OSA, although average oxygen saturation awake and asleep was lower in the endometrial cancer patients. This likely reflects the increased obesity in the endometrial cancer patients. Similar prevalences and severity of OSA between breast and endometrial cancer patients are likely reflective of the age and obesity risk factors, for both cancer and OSA, that were present in both groups.

**Strengths and limitations of this study**

This is the first prospective study of endometrial cancer patients, and the first prospective study of breast cancer patients to use gold standard laboratory polysomnography to assess OSA severity and examine relationships with cancer histopathology. Although limited channel studies have been shown to result in similar clinical outcomes [44], there are differences in the assessment of OSA severity, which may be important. We have chosen to study two female cancer cohorts, allowing for comparisons between the two groups.

Study limitations include the small sample sizes, which may have resulted in an incorrect estimation of prevalence of sleep disordered breathing in the cancer cohorts. Similarly small sample sizes may have impacted on our ability to find any relationships between cancer characteristics and OSA, as has a lack of molecular subtyping of the tumours. The timing of the sleep studies were different in each group because of the different therapies each cancer group underwent. At 12 months, women with breast cancer have been demonstrated to have returned to baseline in terms of sleep symptoms [45]. There is no data on patients with endometrial cancer, however we chose to study these patients within 3 months of treatment, as the majority had surgery only. For those endometrial cancer patients who had radiotherapy or chemotherapy, there was a minimum of 7 months after treatment. These differences in timing may have impacted OSA prevalence or severity, although we did not find any differences between the groups.

**Conclusion**

Women with breast or endometrial cancer have a high prevalence of moderate-severe OSA that may go unrecognised, potentially due to a lack of sleepiness symptoms and an atypical presentation. While we found no relationships between the severity of sleep disordered breathing and histopathological characteristics of cancer in these women, or any differences in OSA severity between the study groups, OSA likely poses an increased anesthetic and surgical risk for these patients during their treatment phase, and should also be considered as a potential contributor to ongoing quality of life issues that may be experienced by breast and endometrial cancer patients in the post-treatment phase.

**Supporting information**

S1 Appendix. (DOCX)

**Acknowledgments**

The authors would like to thank Catherine Kennedy, Annie Stenlake, Masrura Kabir, Alissa Phung, Ragini Gengiah, A/Professor Nirmala Pathmanathan, Associate Professor James French, Dr Kristina Lindemann, Dr Robyn Sayers, Professor Paul Harnett and Professor John...
Wheatley for their assistance with this study, and the Sydney West Translational Cancer Research Centre.

**Author Contributions**

**Conceptualization:** Elisabeth Elder, Gerard Wain, Anna DeFazio, Terence Amis, Kristina Kairaitis.

**Data curation:** Ayey Madut, Veronika Fuchsova, Hong Man, Shabeel Askar, Ritu Trivedi, Kristina Kairaitis.

**Formal analysis:** Veronika Fuchsova, Hong Man, Shabeel Askar, Ritu Trivedi, Anna DeFazio, Terence Amis, Kristina Kairaitis.

**Funding acquisition:** Elisabeth Elder, Christine L. Clarke, Gerard Wain, Anna DeFazio, Terence Amis, Kristina Kairaitis.

**Investigation:** Ayey Madut, Veronika Fuchsova, Hong Man, Shabeel Askar, Ritu Trivedi, Alison Brand, Kristina Kairaitis.

**Methodology:** Ayey Madut, Veronika Fuchsova, Hong Man, Shabeel Askar, Ritu Trivedi, Gerard Wain, Alison Brand, Anna DeFazio, Terence Amis, Kristina Kairaitis.

**Project administration:** Ayey Madut, Veronika Fuchsova, Hong Man, Shabeel Askar, Terence Amis, Kristina Kairaitis.

**Resources:** Kristina Kairaitis.

**Supervision:** Terence Amis, Kristina Kairaitis.

**Validation:** Ayey Madut, Hong Man, Kristina Kairaitis.

**Visualization:** Kristina Kairaitis.

**Writing – original draft:** Elisabeth Elder, Anna DeFazio, Terence Amis, Kristina Kairaitis.

**Writing – review & editing:** Christine L. Clarke, Gerard Wain, Alison Brand, Kristina Kairaitis.

**References**

1. Nieto FJ, Peppard PE, Young T, Finn L, Hla KM, Farre R. Sleep-disordered breathing and cancer mortality: results from the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med. 2012; 186(2):190–4. https://doi.org/10.1164/rccm.201201-0130OC PMID: 22610391

2. Marshall NS, Wong KK, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the busselton health study cohort. J Clin Sleep Med. 2014; 10(4):355–62. https://doi.org/10.5664/jcsm.3600 PMID: 24733978

3. Martinez-Garcia MA, Campos-Rodriguez F, Nagore E, Martorell A, Rodriguez-Peralto JL, Riveiro-Falkenbach E, et al. Sleep-Disordered Breathing Is Independently Associated With Increased Aggressiveness of Cutaneous Melanoma: A Multicenter Observational Study in 443 Patients. Chest. 2018; 154(6):1348–58. https://doi.org/10.1016/j.chest.2018.07.015 PMID: 30059679

4. Martinez-Garcia MA, Martorell-Calatayud A, Nagore E, Valero I, Selma MJ, Chiner E, et al. Association between sleep disordered breathing and aggressiveness markers of malignant cutaneous melanoma. Eur Respir J. 2014; 43(6):1661–8. https://doi.org/10.1183/09031936.00115413 PMID: 24659545

5. Cabezas E, Perez-Warnisher MT, Troncoso MF, Gomez T, Melchor R, Pinillos EJ, et al. Sleep Disordered Breathing Is Highly Prevalent in Patients with Lung Cancer: Results of the Sleep Apnea in Lung Cancer Study. Respiration. 2019; 97(2):119–24. https://doi.org/10.1159/000492273 PMID: 30261487

6. Campos-Rodriguez F, Cruz-Medina A, Selma MJ, Rodriguez-de-la-Borbolla-Altacho M, Sanchez-Vega A, Ripoll-Orts F, et al. Association between sleep-disordered breathing and breast cancer aggressiveness. PloS one. 2018; 13(11). https://doi.org/10.1371/journal.pone.0207591 PMID: 30462710
7. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nature Reviews Cancer. 2015; 15(8):484–98. https://doi.org/10.1038/nrc3967 PMID: 26205341

8. Aune D, Navarro Rosensblatt DA, Chan DS, Vingeliene S, Abar L, Vieira AR, et al. Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Annals Oncol. 2015; 26(8):1635–48. https://doi.org/10.1093/annonc/mdv142 PMID: 25791635

9. Nagle CM, Marquart L, Bain CJ, O'Brien S, Lahmann PH, Quinn M, et al. Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. Eur J Can. 2013; 49(12):2717–26. https://doi.org/10.1016/j.ejca.2013.03.015 PMID: 23583438

10. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Brit J Can. 1957; 11(3):359–77.

11. Mutch DG. The new FIGO staging system for cancers of the vulva, cervix endometrium and sarcomas. Gynecol Oncol. 2009; 115:325–8.

12. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991; 14(6):540–5. https://doi.org/10.1093/sleep/14.6.540 PMID: 1798888

13. Chung F, Subramanyam R, Liao P, Sasaki E, Shapiro C, Sun Y. High STOP-Bang score indicates a high probability of obstructive sleep apnoea. Br J Anaesth. 2012; 108(5):768–75. https://doi.org/10.1093/bja/aes022 PMID: 22401881

14. Chung F, Yang Y, Liao P. Predictive Performance of the STOP-Bang Score for Identifying Obstructive Sleep Apnea in Obese Patients. Obesity Surgery. 2013; 23(12):2050–7. https://doi.org/10.1007/s11695-013-1006-z PMID: 23771818

15. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2012; 8(5):597–619. https://doi.org/10.5664/jcsm.2172 PMID: 23066376

16. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep disordered breathing among middle aged adults. New Engl J Med. 1993; 328:1230–5. https://doi.org/10.1056/NEJM199304293281704 PMID: 8464434

17. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased Prevalence of Sleep-Disordered Breathing in Adults. Am J Epidem iol. 2013; 177(9):1006–14. https://doi.org/10.1093/aje/kws342 PMID: 23589584

18. Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med. 2015; 3(4):310–8. https://doi.org/10.1016/S2213-2600(15)00043-0 PMID: 25682233

19. Resta O, Bonfitto P, Sabato R, De Pergola G, Barbaro MP. Prevalence of obstructive sleep apnoea in a sample of obese women: effect of menopause. Diabetes Nutr Metab. 2004; 17(5):296–303. PMID: 16295052

20. Reinsel RA, Starr TD, O’Sullivan B, Passik SD, Kavey NB. Polysomnographic Study of Sleep in Survivors of Breast Cancer. J Clin Sleep Med. 2015; 11(12):1361–70. https://doi.org/10.5664/jcsm.5264 PMID: 26194735

21. Lindberg E, Benediktsson B, Franklin KA, Holm M, Johannessen A, Jogi R, et al. Women with symptoms of sleep-disordered breathing are less likely to be diagnosed and treated for sleep apnea than men. Sleep Med. 2017; 35:17–22. https://doi.org/10.1016/j.sleep.2017.02.032 PMID: 28619177

22. Lozo T, Komnenov D, Badr MS, Mateika JH. Sex differences in sleep disordered breathing in adults. Respir Physiol Neurobiol. 2017; 245:65–75. https://doi.org/10.1016/j.resp.2016.11.001 PMID: 27836648

23. Morrell MJ, Finn L, McMillan A, Peppard PE. The impact of ageing and sex on the association between sleepiness and sleep disordered breathing. Eur Respir J. 2012; 40(2):386–93. https://doi.org/10.1183/09031936.00177411 PMID: 22421742

24. Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Rein J, Vela-Bueno A, et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med. 2001; 163(3):608–13. https://doi.org/10.1164/ajrccm.163.3.9911064 PMID: 11254512

25. Anttalainen U, Saaresranta T, Alttokallio J, Kalleinen N, Vahlberg T, Virtanen I, et al. Impact of menopause on the manifestation and severity of sleep-disordered breathing. Acta Obstet Gynecol Scand. 2006; 85(11):1381–8. https://doi.org/10.1080/00016340600935649 PMID: 17091421

26. Young T, Finn L, Austin D, Peterson A. Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med. 2003; 167(9):1181–5. https://doi.org/10.1164/rccm.200209-1055OC PMID: 12615621

27. Gozal D, Ham SA, Mokhlesi B. Sleep Apnea and Cancer: Analysis of a Nationwide Population Sample. Sleep. 2016; 39(8):1493–500. https://doi.org/10.5665/sleep.6004 PMID: 27166241
28. Pataka A, Bonsignore MR, Ryan S, Riha RL, Pepin JL, Schiza S, et al. Cancer prevalence is increased in females with sleep apnoea: data from the ESADA study. Eur Respir J. 2019; 53(6). https://doi.org/10.1183/13993003.00091-2019 PMID: 31109987

29. Chang WP, Liu ME, Chang WC, Yang AC, Ku YC, Pai JT, et al. Sleep apnea and the subsequent risk of breast cancer in women: a nationwide population-based cohort study. Sleep medicine. 2014; 15(9):1016–20. https://doi.org/10.1016/j.sleep.2014.05.026 PMID: 25085620

30. Choi JH, Lee JY, Han KD, Lim YC, Cho JH. Association between obstructive sleep apnoea and breast cancer: The Korean National Health Insurance Service Data 2007–2014. Scientific Reports. 2019; 9. https://doi.org/10.1038/s41598-019-55551-7 PMID: 31836779

31. Huang TY, Lin BM, Markt SC, Stampfer MJ, Laden F, Hu FB, et al. Sex differences in the associations of obstructive sleep apnoea with epidemiological factors. Eur Respir J. 2018; 51(3). https://doi.org/10.1183/13993003.02421-2017 PMID: 29449424

32. Bouloukaki I, Mermigkis C, Markakis M, Pataka A, Alexaki I, Ermidou C, et al. Cardiovascular Effect and Symptom Profile of Obstructive Sleep Apnea: Does Sex Matter? J Clin Sleep Med. 2019; 15(12):1737–45. https://doi.org/10.5664/jcsm.8074 PMID: 31855159

33. Ljunggren M, Lindberg E, Franklin KA, Ohagen P, Larsson M, Theorell-Haglow J, et al. Obstructive sleep apnea during rapid eye movement sleep is associated with early signs of atherosclerosis in women. Sleep. 2018; 41(7). https://doi.org/10.1093/sleep/zsy099 PMID: 29762755

34. Gouveris H, Bahr K, Jahn C, Matthias C, Simon P. The Apnea-Hypopnea Index Underestimates Systemic Inflammation in Women with Sleep-Disordered Breathing. Journal of women's health. 2018; 27(7):920–6. https://doi.org/10.1089/jwh.2017.6819 PMID: 29630436

35. Chan MTV, Wang CY, Seet E, Tam S, Lai HY, Chew EFF, et al. Association of Unrecognized Obstructive Sleep Apnea With Postoperative Cardiovascular Events in Patients Undergoing Major Noncardiac Surgery. JAMA. 2019; 321(18):1788–98. https://doi.org/10.1001/jama.2019.4783 PMID: 31087023

36. Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447):67–73. https://doi.org/10.1038/nature12113 PMID: 23636398

37. Coboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61–70. https://doi.org/10.1038/nature11412 PMID: 23000897

38. Verduzco D, Lloyd M, Xu L, Ibrahim-Hashim A, Balagurunathan Y, Gatenby RA, et al. Intermittent hypoxia selects for genotypes and phenotypes that increase survival, invasion, and therapy resistance. PloS one. 2015; 10(3):e0120958. https://doi.org/10.1371/journal.pone.0120958 PMID: 25911878

39. Rao MN, Blackwell T, Redline S, Stefanick ML, Ancoli-Israel S, Stone KL, et al. Association between sleep architecture and measures of body composition. Sleep. 2009; 32(4):483–90. https://doi.org/10.1093/sleep/32.4.483 PMID: 1913142

40. Yetton BD, McDevitt EA, Cellini N, Shelton C, Mednick SC. Quantifying sleep architecture dynamics and individual differences using big data and Bayesian networks. PloS one. 2018; 13(4):e0194604–e. https://doi.org/10.1371/journal.pone.0194604 PMID: 29641599

41. Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? J Clin Oncol. 2011; 29(26):3517–22. https://doi.org/10.1200/JCO.2011.36.1154 PMID: 21825266

42. Armbruster SD, Song J, Gatus L, Lu KH, Basen-Engquist KM. Endometrial cancer survivors’ sleep patterns before and after a physical activity intervention: A retrospective cohort analysis. Gynecol Oncol. 2018; 149(1):133–9. https://doi.org/10.1016/j.ygyno.2018.01.028 PMID: 29395314

43. Baker FC, de Zambotti M, Colrain IM, Bei B. Sleep problems during the menopausal transition: prevalence, impact, and management challenges. Nat Sci Sleep. 2018; 10:73–95. https://doi.org/10.2147/NSS.S125807 PMID: 29445307

44. Chai-Coetzter CL, Antic NA, Hamilton GS, McArdle N, Wong K, Yee BJ, et al. Physician Decision Making and Clinical Outcomes With Laboratory Polysomnography or Limited-Channel Sleep Studies for Obstructive Sleep Apnea: A Randomized Trial. Ann Intern Med. 2017; 166(5):332–40. https://doi.org/10.7326/M16-1301 PMID: 28114683

45. Ancoli-Israel S, Liu L, Rissling M, Natarajan L, Neikrug AB, Palmer BW, et al. Sleep, fatigue, depression, and circadian activity rhythms in women with breast cancer before and after treatment: a 1-year longitudinal study. Supportive care in cancer. 2014; 22(9):2535–45. https://doi.org/10.1007/s00520-014-2204-5 PMID: 24733634